Fecundis has reached an important scientific milestone with the publication of a new clinical study in the Journal of Translational Medicine, showing that HyperSperm™ improves key embryo development outcomes in patients undergoing in vitro fertilization.
The multicenter prospective study, conducted in Argentina in collaboration with 3 fertility clinics — Pregna, Fertya and In Vitro Buenos Aires — evaluated HyperSperm in 41 IVF patients using a sibling-oocyte design.
This type of study is particularly relevant in assisted reproduction because oocytes from the same patient are divided between two conditions. In this case, part of the oocytes were inseminated with sperm prepared using standard laboratory procedures, while the other part were inseminated with sperm prepared using the HyperSperm protocol. This design helps reduce patient-to-patient variability and allows a more direct comparison between both sperm preparation approaches.
Why sperm preparation matters in IVF
In assisted reproduction, sperm assessment has traditionally focused on concentration, motility and morphology. These parameters are essential, but they do not fully describe whether a sperm cell is functionally prepared to fertilize the oocyte and support embryo development.
Before fertilization occurs naturally, sperm cells undergo a complex biological process known as capacitation. During this process, sperm acquire the functional competence required to interact with the oocyte. However, conventional IVF sperm preparation methods mainly recover motile sperm and do not fully reproduce the dynamic environment of the female reproductive tract.
HyperSperm was developed to address this gap. Rather than only selecting sperm, the technology is designed to optimize sperm function by recreating key stages of capacitation before fertilization.
Key findings from the clinical study
The study showed that HyperSperm increased blastocyst development compared with standard sperm preparation.
Key results included:
- Higher blastocyst development rate: 55.6% with HyperSperm vs. 47.9% with standard preparation.
- Higher utilizable blastocyst rate: 48.9% with HyperSperm vs. 40.1% with standard preparation.
- In 5 cases where the control arm produced no blastocysts, the HyperSperm arm generated at least one blastocyst.
- In the subgroup of embryos analyzed by PGT-A, a higher proportion of euploid embryos was observed in the HyperSperm group.
To date, 11 babies have been born to date following the use of HyperSperm, with no abnormalities reported, further supporting the safety profile observed so far.
More embryos, more clinical options
In IVF, every viable blastocyst matters. A higher number of embryos with transfer or cryopreservation potential can expand the clinical options available within a single treatment cycle.
This is especially relevant for patients who obtain few embryos or who may otherwise reach the end of a cycle without a transferable blastocyst. In this context, improving sperm preparation before fertilization may have a meaningful impact on the efficiency of IVF workflows and on the number of opportunities available to patients.
A shift from sperm selection to sperm optimization
The publication of this study reinforces Fecundis’s scientific approach: moving beyond conventional sperm recovery and toward sperm function optimization.
While many sperm preparation technologies focus on selecting the best sperm from a sample, HyperSperm is based on a different concept: supporting the biological processes sperm need to acquire functional competence before fertilization.
These findings add to the growing evidence that sperm physiology plays an active role in early embryo development. They also support the idea that advanced sperm biology can become an important driver of innovation in IVF laboratories.
For Fecundis, this publication marks a strategic step forward in the development of HyperSperm and strengthens the company’s position as a biotechnology company focused on improving assisted reproduction through science-driven sperm technologies.
Reference
Oscoz-Susino N. et al. A multicenter, prospective sibling oocyte study revealed that HyperSperm™ improves the number and quality of embryos in patients undergoing in vitro fertilization. Journal of Translational Medicine. 2026.
Source: https://link.springer.com/article/10.1186/s12967-026-08261-4